Teva Pharmaceutical Industries (TEVA) Exchange Rate Effect (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Exchange Rate Effect for 18 consecutive years, with -$5.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Exchange Rate Effect changed 0.0% year-over-year to -$5.0 million; the trailing twelve-month figure through Jun 2026 stood at -$41.0 million (down 315.79% YoY), and the FY2025 full-year result was $21.0 million, up 112.07% from the prior year.
• Exchange Rate Effect advanced to -$5.0 million in Q2 2026 per TEVA's latest filing, from -$17.0 million in the prior quarter.
• Across five years, Exchange Rate Effect topped out at $146.0 million in Q4 2022 and bottomed at -$123.0 million in Q2 2022.
• Historically, Exchange Rate Effect has averaged -$18.2 million across 5 years, with a median of -$13.5 million in 2025.
• The widest YoY moves for Exchange Rate Effect: up 404.17% in 2022, down 2360.0% in 2022.
• Over 5 years, Exchange Rate Effect stood at $146.0 million in 2022, then sank by 53.42% to $68.0 million in 2023, then plunged by 277.94% to -$121.0 million in 2024, then jumped by 91.74% to -$10.0 million in 2025, then soared by 50.0% to -$5.0 million in 2026.
• According to Business Quant data, Exchange Rate Effect over the past three periods registered -$5.0 million, -$17.0 million, and -$10.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.